Karsten Schmidt

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

François-Xavier Lescure, Hitoshi Honda, Robert Fowler et al. · The Lancet Respiratory Medicine · 2021 · 248 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study

Alexis Tabah, Niccolò Buetti, Quentin Staiquly et al. · Intensive Care Medicine · 2023 · 246 citations · Full text

Veterinary Medicine, Infectious Diseases, Critical Care Medicine +15

Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial

Stefan Hagel, Friedhelm Bach, Thorsten Brenner et al. · Intensive Care Medicine · 2022 · 171 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19

Birte Möhlendick, Kristina Schönfelder, Katharina Breuckmann et al. · Pharmacogenetics and Genomics · 2021 · 136 citations · Full text

Life Sciences, Infectious Diseases, Molecular Genetics +11

O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone

Renee Bailey, Mark G. Kris, Michael Wolf et al. · Lung Cancer · 2003 · 96 citations

Medicine, Oncology, Pharmacology +14